{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-160347","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2026-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.172774+00:00","generated_at":"2026-05-15T05:35:17.027082+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Tyra Biosciences expands board to ten, appoints Habib J. Dable as Class II director","bullets":["Board increased from nine to ten members; Dable appointed effective April 16, 2026, with term expiring at 2026 annual meeting.","Dable previously President & CEO of Acceleron Pharma (acquired by Merck in 2021) and advisor at RA Capital since April 2022.","Received option to purchase 44,400 shares vesting equally over 36 months; cash compensation per Non-Employee Director Program.","Board determined Dable is independent under Nasdaq listing requirements."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-160347","json":"https://secwatch.observer/filing/0001193125-26-160347.json","markdown":"https://secwatch.observer/filing/0001193125-26-160347.md","text":"https://secwatch.observer/filing/0001193125-26-160347.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526160347/0001193125-26-160347-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526160347/d17006d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:35:17.027082+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}